The Federal Trade Commission (FTC) has filed an amicus brief in an antitrust case, challenging drug manufacturer Amgen's alleged illegal acquisition of exclusive patent rights for its biologic drug, Enbrel. This action aims to protect competition within the vital biologic drug markets.
The brief supports allegations that Amgen manipulated patent applications to cover Enbrel, a medication used to treat rheumatoid arthritis and other inflammatory conditions. This strategy, the FTC contends, allowed Amgen to unlawfully extend its monopoly over the drug.
The FTC's involvement underscores its commitment to preventing anti-competitive practices that could hinder access to essential medications and stifle innovation in the pharmaceutical industry.